AX-2026-042364

Semax · 10 mg declared · Hunan Aslsen Technology Co., Ltd. · lot HOMO-2602-S3200

PASSPURITY ONLY

Report ID: AX-2026-042364
Compound: Semax
Compound class: Neuroactive and cognitive peptides
Supplier: Homopeptide — Hunan Aslsen Technology Co., Ltd.
Batch / lot: HOMO-2602-S3200
Declared label claim: 10mg
Laboratory: Nordanalyt Laboratories
Assay date: 28 Mar 2026
Submitted: 09 Apr 2026
Quarter: 2026-Q1
Submitter: s.bakker
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the neuroactive and cognitive peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 35 min gradient, 214 nm	99.58	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.42	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — N-acetyl semax (+42 Da)	0.26	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	9.14	%	≤ 12.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.20	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.18	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear after 90 s gentle swirling, no particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.07	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 35 min gradient	8.11	min	8.14 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.14	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	65,892	—	≥ 20,000	PASS
Resolution to nearest impurity	vs diketopiperazine (−18 Da)	1.44	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 35 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 65,892, and skew follows the reported asymmetry factor of 1.14. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.26 % impurity against a 99.58 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Semax — main peak	8.11	4,839,897	99.58	—
2	N-acetyl semax (+42 Da)	8.60	12,637	0.26	+42.011
3	diketopiperazine (−18 Da)	8.30	4,860	0.10	-18.011
4	des-Met (−131 Da)	8.34	1,944	0.04	-131.040
5	Met1 sulfoxide (+16 Da)	7.69	972	0.02	+15.995
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.05	99.58	divergence -0.61 pp vs batch median
Total impurities (% area)	0.95	0.42
Largest single impurity (% area)	not stated	0.26
Water (%)	not stated	9.14
Counter-ion (%)	8.6	5.20
Peptide content (%w/w)	87.3	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → third-party forwarder (1 d) → laboratory (courier, cold pack, 12 d) → assay.
Assay date: 28 Mar 2026
Submitted to the index: 09 Apr 2026
Laboratory: Nordanalyt Laboratories, Uppsala, Sweden
Method basis: 35 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

buyer_sourced09 Apr 2026

Ordering under an unremarkable name and address is the whole method. It requires no cooperation from anybody and it produces the strongest evidence this index holds.

diode_array09 Apr 2026

Peak purity by spectral comparison across the main peak flags co-elution where chromatography cannot resolve it. It does not quantify the co-eluting species, but it establishes that one exists.

Section 7

Related records

Same batch — lot HOMO-2602-S3200 n=11

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042354	HOMO-2602-S3200	Janoshik	2026-Q1	99.65	8.46	—	Buyer-sourced	0	PASS
AX-2026-042355	HOMO-2602-S3200	Janoshik	2026-Q1	99.56	9.38	89.9	Buyer-sourced	1	MARGINAL
AX-2026-042356	HOMO-2602-S3200	Janoshik	2026-Q1	99.70	9.35	—	Buyer-sourced	0	PASS
AX-2026-042357	HOMO-2602-S3200	Janoshik	2026-Q1	99.93	8.98	—	Buyer-sourced	0	PASS
AX-2026-042358	HOMO-2602-S3200	Janoshik	2026-Q1	99.51	9.06	—	Buyer-sourced	0	PASS
AX-2026-042359	HOMO-2602-S3200	Medutest	2026-Q1	99.66	9.30	—	Buyer-sourced	0	PASS
AX-2026-042360	HOMO-2602-S3200	Janoshik	2026-Q1	99.69	8.98	—	Buyer-sourced	0	PASS
AX-2026-042361	HOMO-2602-S3200	Janoshik	2026-Q1	99.91	8.70	91.5	Buyer-sourced	0	PASS
AX-2026-042362	HOMO-2602-S3200	PeptideMeter	2026-Q1	99.69	9.09	—	Buyer-sourced	0	PASS
AX-2026-042363	HOMO-2602-S3200	PeptideMeter	2026-Q1	99.56	9.71	—	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Semax records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042519	Homopeptide	HOMO-2605-S5227	Medutest	2026-Q3	99.75	5.55	—	Buyer-sourced	PASS
AX-2026-042517	Homopeptide	HOMO-2605-S5227	Janoshik	2026-Q3	99.92	5.88	—	Buyer-sourced	PASS
AX-2026-042518	Homopeptide	HOMO-2605-S5227	Janoshik	2026-Q3	99.76	5.61	—	Buyer-sourced	PASS
AX-2026-042524	Homopeptide	HOMO-2605-S5227	Janoshik	2026-Q3	99.93	5.75	100.9	Supplier-supplied	PASS
AX-2026-042516	Homopeptide	HOMO-2605-S5227	Janoshik	2026-Q3	99.93	5.87	95.1	Buyer-sourced	PASS
AX-2026-042522	Homopeptide	HOMO-2605-S5227	Nordanalyt	2026-Q3	99.93	5.49	—	Buyer-sourced	PASS
AX-2026-042520	Homopeptide	HOMO-2605-S5227	Medutest	2026-Q3	99.93	6.12	—	Buyer-sourced	PASS
AX-2026-042514	Homopeptide	HOMO-2605-S5227	Janoshik	2026-Q3	99.59	5.48	97.0	Buyer-sourced	PASS

Other recent Homopeptide records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042437	Retatrutide	HOMO-2605-V4718	Nordanalyt	2026-Q3	98.68	3.67	102.8	Buyer-sourced	PASS
AX-2026-042424	Semaglutide	HOMO-2604-X3806	PeptideMeter	2026-Q3	98.85	4.87	92.0	Buyer-sourced	PASS
AX-2026-042503	IGF-1 LR3	HOMO-2607-P5131	Janoshik	2026-Q3	99.36	5.99	—	Buyer-sourced	PASS
AX-2026-042492	SS-31 (Elamipretide)	HOMO-2604-D5484	Medutest	2026-Q3	99.93	2.40	—	Buyer-sourced	PASS
AX-2026-042491	SS-31 (Elamipretide)	HOMO-2604-D5484	Kestrel	2026-Q3	99.93	3.24	—	Supplier-supplied	PASS
AX-2026-042473	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.01	5.00	—	Buyer-sourced	PASS
AX-2026-042441	Retatrutide	HOMO-2605-V4718	Medutest	2026-Q3	98.93	4.22	—	Buyer-sourced	PASS
AX-2026-042474	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.18	5.44	—	Buyer-sourced	PASS